Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Saniona AB ( (SE:SANION) ) has issued an announcement.
Saniona has entered an exclusive licensing agreement with Jazz Pharmaceuticals for the global development and commercialization of SAN2355, a preclinical asset targeting epilepsy. Saniona will receive $42.5 million upfront, with potential milestone payments and royalties, while Jazz will lead the development and commercialization efforts, enhancing its neuroscience pipeline.
The most recent analyst rating on (SE:SANION) stock is a Hold with a SEK9.00 price target. To see the full list of analyst forecasts on Saniona AB stock, see the SE:SANION Stock Forecast page.
More about Saniona AB
Saniona is a clinical-stage biopharmaceutical company focused on developing innovative treatments for neurological and psychiatric disorders. Its pipeline includes SAN2219 for epilepsy and SAN2465 for major depressive disorder, and it has strategic collaborations with companies like Jazz Pharmaceuticals and Acadia Pharmaceuticals.
Average Trading Volume: 710,058
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.15B
For an in-depth examination of SANION stock, go to TipRanks’ Overview page.